ERBB3 and breast carcinoma: Concurrent expression of HER2 and HER3 activated PI3K/AKT signaling and was connected to resistance to a variety of chemotherapeutics, including doxorubicin, paclitaxel, etoposide, 5-fluorouracil, and camptothecin in breast cancer cell lines[37].